|
Wednesday, August 11, 2021, 5:00 PM – 6:00 PM Eastern Time (ET)
A Conversation with the Investigators: Perspectives on the Management of Head and Neck CancerA Live CME/MOC Webinar Held Adjunct to the 2021 ASCO Annual Meeting
Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page. Join us on Wednesday, August 11th for this CME/MOC-accredited webinar Faculty
Barbara Burtness, MD
Professor of Medicine Yale School of Medicine Co-Leader, Developmental Therapeutics Program Director, Yale Head and Neck SPORE Yale Cancer Center New Haven, Connecticut Ezra Cohen, MD Professor of Medicine Chief, Division of Hematology-Oncology Associate Director, Clinical Science Moores Cancer Center at UC San Diego Health La Jolla, California
Robert L Ferris, MD, PhD
Director, UPMC Hillman Cancer Center Hillman Professor of Oncology Associate Vice Chancellor for Cancer Research Co-Director, Tumor Microenvironment Center Professor, Departments of Otolaryngology, Immunology, and Radiation Oncology Pittsburgh, Pennsylvania Moderator Neil Love, MD Research To Practice Miami, Florida Topics for discussion
Target Audience Learning Objectives
CME Credit Form Accreditation Statement Credit Designation Statement American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Disclosure Policy FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process: Dr Burtness — Advisory Committee: AstraZeneca Pharmaceuticals LP, Chinook Therapeutics, Cue Biopharma, Debiopharm Group, IO Biotech, Ipsen Biopharmaceuticals Inc, Kura Oncology, MacroGenics Inc, Merck, Nanobiotix, Nuvelution Pharma Inc, Rakuten Medical Inc; Consulting Agreements (Grant/Research/Clinical Trial Support): Bristol-Myers Squibb Company, Cue Biopharma, Merck. Dr Cohen — Board of Directors: PsiOxus; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Eisai Inc, Gilead Sciences Inc, Janssen Biotech Inc, Kinnate Biopharma, Merck, Merck Sharp & Dohme Corp, Mirati Therapeutics, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc; Ownership Interest: Shares held in Kinnate Biopharma and Primmune Therapeutics. Dr Ferris — Advisory Committee: Bristol-Myers Squibb Company, EMD Serono Inc, Instil Bio Inc, Lifescience Dynamics Ltd, MacroGenics Inc, Merck, Numab, Oncocyte, Pfizer Inc, Rakuten Medical; Consulting Agreements: Bicara Therapeutics, Chinook Therapeutics, F Hoffmann-La Roche Ltd, Genocea, Kowa Research Institute Inc, Mirati Therapeutics, Novasenta, Sanofi Genzyme, Zymeworks; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Merck, Novasenta, Tesaro, A GSK Company; Stock: Novasenta.MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS Supporters |